Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00600496 · ClinicalTrials.gov registry record · Phase 1

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
140
Enrollment target
4
Study locations

NCT00600496 is a Phase 1 study of Breast Cancer and Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 140 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00600496, a Phase 1 study of Breast Cancer and Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
4
Study locations

Study Summary

This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies

Conditions Studied

Breast Cancer Lung Cancer Melanoma Colon Cancer Breast Neoplasms Kidney Cancer Colonic Cancer Colon Neoplasms

Interventions

  • DRUG Docetaxel
  • DRUG Dacarbazine
  • DRUG Temsirolimus
  • DRUG Erlotinib
  • DRUG AZD6244

Study Locations (4)

Michigan

  • Research Site - Detroit

Pennsylvania

  • Research Site - Philadelphia

Tennessee

  • Research Site - Nashville

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2007-12-14
Est. Completion 2025-12-31
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00600496

The ClinicalTrials.gov registry entry for NCT00600496 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.

NCT00600496 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00600496 about?

NCT00600496 is a clinical study titled "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)". This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies ...

What is the current status of trial NCT00600496?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2007-12-14. Estimated completion is 2025-12-31.

What conditions does trial NCT00600496 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Melanoma, Colon Cancer, Breast Neoplasms.

What interventions are being tested in trial NCT00600496?

The interventions under investigation include: Docetaxel (DRUG), Dacarbazine (DRUG), Temsirolimus (DRUG), Erlotinib (DRUG), AZD6244 (DRUG).

Who is sponsoring clinical trial NCT00600496?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00600496 being conducted?

This trial has 4 study locations across Michigan, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.